Aspen Neuroscience (ASPE) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspen Neuroscience is the larger company by market cap ($361.2 million vs $328.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASPE | LRMR |
|---|---|---|
| Share price | $12.42 | $3.14 |
| Market cap | $361.16M | $328.55M |
| 1-day change | +0.24% | -2.48% |
| YTD return | — | -17.59% |
| 1-year return | — | -11.80% |
| 5-year return | — | -68.97% |
| EPS (TTM) | $-4.89 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-165.67M |
| 52-week high | $14.90 | $6.42 |
| 52-week low | $11.20 | $1.92 |
| Distance from 52-week high | -16.64% | -51.09% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +352.23% |
| Average volume | 352.42K | 1.38M |
| Shares outstanding | 29.08M | 104.63M |
| Employees | 120 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspen Neuroscience
ASPE stock →Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
ASPE vs LRMR FAQ
Which is bigger, Aspen Neuroscience or Larimar Therapeutics?
Aspen Neuroscience (ASPE) is larger, with a market capitalization of $361.16M compared with $328.55M for Larimar Therapeutics (LRMR).
Are Aspen Neuroscience and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.